MedTrace Logo

Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

NCT02238535 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-09-23

No results posted yet for this study

Summary

To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.

Conditions

  • Residual Pulmonary Hypertension

Interventions

DRUG

Ventavis

DRUG

Warfarin

Sponsors & Collaborators

  • Meshalkin Research Institute of Pathology of Circulation

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-03-31
Completion
2016-10-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238535 on ClinicalTrials.gov